Eagle Pharmaceuticals, Inc. (EGRX) Financials

EGRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2023 404.8 million 152.8 million
March 31, 2023 414.2 million 171.3 million
Dec. 31, 2022 406.2 million 172.6 million
Sept. 30, 2022 390.1 million 154.7 million

EGRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2023 -132000 4.2 million
March 31, 2023 -33.6 million 4.6 million
Dec. 31, 2022 37.5 million 4.1 million
Sept. 30, 2022 -13.2 million 3.5 million

EGRX Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
June 30, 2023 5.2 million
March 31, 2023 5.8 million
Dec. 31, 2022 8.2 million
Sept. 30, 2022 -3.5 million

EGRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2023 15.4 million 61.9 million 1.4 million
March 31, 2023 21.9 million 68.8 million 1.6 million
Dec. 31, 2022 55.3 million 60.0 million 5.3 million
Sept. 30, 2022 15.4 million 28.3 million 3.4 million

EGRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2023 13.2 million
March 31, 2023 13.2 million
Dec. 31, 2022 13.1 million
Sept. 30, 2022 13.2 million

EGRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2023 6000 9.8 million 27.7 million 4.4 million
March 31, 2023 58000 9.3 million 28.0 million 3.7 million
Dec. 31, 2022 10000 7.2 million 24.2 million 3.4 million
Sept. 30, 2022 10000 9.3 million 23.5 million 1.7 million

EGRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2023 64.6 million 16.9 million
March 31, 2023 66.3 million 17.3 million
Dec. 31, 2022 60.7 million 19.9 million
Sept. 30, 2022 65.9 million 23.7 million

EGRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

EGRX

Price: $0.46

52 week price:
0.09
3.87

Earnings Per Share: 0.07 USD

P/E Ratio: 2.14

Exchange: OEM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 130600

Ebitda: 25.9 million

Market Capitalization: 6.2 million

Links: